Oligonucleotide Pharmacology and Formulation: G3139 Anti-BCL2 Phosphorothioate In Stealth® Liposomes and Gel Implants

REFERENCES

• Srinivasan , S. K. and Iversen , P. 1995 . J. Clin. Lab. Anal. , 9 : 129 – 137 .
   PubMed Web of Science ®Google Scholar
• Cotter , F. E. , Johnson , P. , Hall , P. and Pocock , C. 1994 . Oncogene , 9 : 3049 – 3055 .
   PubMed Web of Science ®Google Scholar
• Webb , A. , Cunningham , D. , Cotter , F. , Hill , M. , Clarke , P. , di Stefano , F. , Viner , C. , Prendeville , J. , Rahal , S. and Dziewanowska , Z. 1996 . Annals Oncology 7 (Supplement 3) , Abstract 101
   Google Scholar
• Lebedev , A. V. , Raynaud , F. , Dizik , M. , Beck , T. A. , Jaeger , J. A. , Brown , B. D. , Cunningham , D. , Webb , A. , McCampbell , E. , Riley , T. , Judson , I. and Woodle , M. C. 1996 . Nucleosides and Nucleotides , this issue
   PubMedGoogle Scholar
• Woodle , M. C. 1995 . Adv. Drug Del. Rev. , 16 : 249 – 265 .
   Web of Science ®Google Scholar